0LIF Stock Chart & Stats
$25.14
$0.12(0.46%)
At close: 4:00 PM EDT
$25.14
$0.12(0.46%)
Day’s Range― - ―
52-Week Range$18.00 - $41.50
Previous CloseN/A
Volume710.00
Average Volume (3M)1.60K
Market Cap
$2.45B
Enterprise Value$2.89K
Total Cash (Recent Filing)$292.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Nov 04, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.84
Shares Outstanding98,489,230
10 Day Avg. Volume684
30 Day Avg. Volume1,600
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)-28.35
Price to Sales (P/S)3.37
P/FCF Ratio-4.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$52.07Price Target Upside107.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-4.33
Revenue Forecast (FY)$748.30M
Bulls Say, Bears Say
Bulls Say
Scaling Revenue & High Gross MarginsUltragenyx has shown durable top-line scaling from $351M to $717M TTM alongside very high gross margins (~84–95%). High product-level margins provide structural operating leverage, supporting long-term profitability if SG&A and R&D are controlled and demand remains stable.
Diversified Commercial Portfolio & GeographyMultiple marketed therapies across distinct rare-disease indications and broad geographic reach reduce single-product dependency. Growing patient counts across regions and established specialty distribution create a more resilient revenue base and improve odds of sustained adoption over the medium term.
Regulatory Catalysts And Launch ReadinessClear near-term regulatory decisions and a pivotal readout can structurally reshape revenue and margins via potential product launches. Management has launch infrastructure, payer engagements and plans to monetize PRVs, which together provide credible routes to scale commercial revenues and non-dilutive capital if approvals occur.
Bears Say
Large And Persistent Cash BurnSustained negative operating and free cash flow requires repeated external funding or asset monetization, increasing refinancing and dilution risk. Even with quarter-to-quarter improvement, this structural cash consumption limits optionality for investing in launches or absorbing clinical setbacks without new capital.
Negative Equity & Prior Debt SpikeThe move to negative equity and a prior large debt increase materially weakens balance-sheet flexibility. This structural weakness raises refinancing, covenant and counterparty risks, constraining strategic choices and making the company more dependent on successful approvals or monetization to restore financial strength.
High Operating Expenses Vs RevenueOperating costs (R&D+SG&A) significantly exceed gross profit despite strong margins, producing large net losses and a structural negative net margin. Without sustained double-digit revenue growth or targeted cost reductions, profitability targets hinge on execution and successful new product launches.
Ultragenyx Pharmaceutical News
0LIF FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest share price was $18.00 and its highest was $41.50 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Ultragenyx Pharmaceutical’s market cap is $2.45B.
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Nov 04, 2026 which is in 90 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Aug 04, 2026. The company reported -$0.9 earnings per share for the quarter, beating the consensus estimate of -$1.218 by $0.318.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -1.01.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 98,489,230 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$0.9 in its last earnings report, beating expectations of -$1.218. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Currently, no hedge funds are holding shares in GB:0LIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ultragenyx Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.07 (107.11% Upside)
$52.07 (107.11% Upside)
Blogger Sentiment
Bullish
GB:0LIF Sentiment 75%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $788.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.21%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
0LIF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Positive overall: the call highlighted record quarterly revenue, broad-based product growth (including Evkeeza +50% YoY), expanding patient counts across multiple geographies, improving cash consumption versus Q1, and clear near-term catalysts (two PDUFAs and a pivotal readout). Management articulated a credible path to profitability in 2027 with expense discipline and potential non-dilutive PRV monetization. Offsetting risks include a sizable operating loss and expense run-rate, reliance on binary regulatory outcomes, an unmet primary outcome for setrusumab requiring possible new trials, and readout/regulatory uncertainty for GTX-102, but these are framed as manageable and addressable within management's plan.View all GB:0LIF earnings summaries0LIF Stock 12 Month Forecast
Average Price Target
$52.07
▲(107.11% Upside)
Technical Analysis
Travere Therapeutics
―
Xenon
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Mineralys Therapeutics, Inc.
―